Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: A Hellenic oncology research group multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 161-168

  Kentepozidis, N ^a   Soultati, A ^a   Giassas, S ^b   Vardakis, N ^c   Kalykaki, A ^c   Kotsakis, A ^c   Papadimitraki, E ^c   Pantazopoulos, N ^b   Bozionellou, V ^c   Georgoulias, V ^c  

^a Leof P Kanellopoulou   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Carboplatin; Paclitaxel; Prostate cancer; Salvage treatment

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PACLITAXEL; PREDNISOLONE;

ADULT; ADVERSE OUTCOME; AGED; ALLERGY; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FATIGUE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; ORCHIECTOMY; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84863423876     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1896-9     Document Type: Article

References (43)

1. Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone refractory prostate cancer? Cancer 109(3):477-486 (Pubitemid 46190955)
2. Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406
3. Gregory CW, Johnson RT Jr, Mohler JL et al (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898 (Pubitemid 32691931)
4. Taplin ME, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
5. Taplin ME, Bubley GJ, Ko YJ et al (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515 (Pubitemid 29269089)
6. Balk SP (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-138; discussion, 138-139
7. Huang J, diSant'Agnese PA (2002) Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts S (ed) Advances in oncology: the expanding role of octreotide. Bio-Scientifica Ltd., Bristol, pp 243-262
8. Hatem A, Jra A, Mokb T (2008) Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients'survival and quality of life. Anticancer Drugs 19:645-653
9. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
10. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda H et al (2005) Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy resistant hormone-refractory prostate cancer: a pilot study. Urology 65:543-548 (Pubitemid 40386006)
11. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
12. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520 (Pubitemid 39315318)
13. Petrylak DP (2007) New paradigms for advanced prostate cancer. Rev Urol 9(Suppl 2):S3-S12
14. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK (2005) Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 4:86-90 (Pubitemid 41474602)
15. Cabrespine A, Guy L, Khenifar E, Curé H, Fleury J, Penault-Llorca F, Kwiatkowski F, Barthomeuf C, Chollet P, Bay JO (2006) Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 67:354-359 (Pubitemid 43189855)
16. Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a Phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080 (Pubitemid 34791096)
17. Berry W, Friedland D, Fleagle J et al (2006) A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 5:131-137
18. Kelly WK, Curley T, Slovin S et al (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53 (Pubitemid 32063478)
19. Urakami S, Igawa M, Kikuno N et al (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168:2444-2450 (Pubitemid 35402636)
20. Oh WK, Hagmann E, Manola J et al (2005) A Phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:284-289 (Pubitemid 40075806)
21. Oh WK, Halabi S, Kelly WK et al (2003) A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 98:2592-2598 (Pubitemid 37509522)
22. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK (2010) Efficacy of carboplatin-taxane combinations in the management of castration resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21:312-318
23. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a single formula based on renal function. J Clin Oncol 7:1748-1756 (Pubitemid 19272848)
24. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467 (Pubitemid 29517916)
25. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
26. De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376(9747):1147-1154
27. De Bono JS, Logothetis CJ, Fizazi K et al. (2010) Abiraterone acetate plus low-dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. 35th ESMO Congress, 2010 Oct 8-12, Milan, Italy. Ann Oncol 21(Suppl 8):viii
28. Loriot Y, Massard C, Gross-Goupil M et al (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46:1770-1772
29. Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM (2010) Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol 29(6):676-681 [Epub 2010 May 7]
30. Sella A, Yarom N, Zisman A, Kovel S (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76(6):442-446 [Epub 2009 May 5]
31. Mathew P, DiPaola R (2007) Taxane refractory prostate cancer. J Urol 178:S36-S41 (Pubitemid 47211164)
32. Valero V, Jones S, Von Hoff D et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362-3368 (Pubitemid 28481633)
33. Taguchi T, Aihara T, Takatsuka Y et al (2004) Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 10:509-513 (Pubitemid 39524984)
34. Seidman A, Hochhauser D, Gollub M et al (1996) Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884
35. Snyder JP, Nettles JH, Cornett B et al (2001) The binding conformation of taxol in b-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 98:5312-5316 (Pubitemid 32397125)
36. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G (2010) Phase II study of docetaxel retreatment in docetaxel-pretreated castration-resistant prostate cancer. B J U 107:234-239
37. Ross RW, Beer TM, Jacobus S et al (2008) A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer 112:521-526 (Pubitemid 351186193)
38. Colloca G, Venturino A, Checcaglini F (2011) Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review. Med Oncol [Epub ahead of print]
39. Eymard J-C, Oudard S, Gravis G, Ferrero J-M, Theodor C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel sensitive prostate cancer: a retrospective multicentre study. BJUI 106:974-978
40. Buonerba C, Palmieri G, Di Lorenzo G (2010) Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol 58(4):636-637 [Epub 2010 Jun 23]
41. Nakabayashi M, Sartor O, Jacobus S et al (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101:308-312
42. Paller CJ, Antonarakis E, Cabazitaxel S (2011) A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design Dev Ther 5:117-124
43. De Bono JS, Sartor O (2011) Cabazitaxel for castration-resistant prostate cancer - author's reply. Lancet 377(9760):122-123